AI Investment Boom, Agentic AI & CRISPR Breakthroughs | Super Summit Investor Panel

Why It Matters

AI‑biotech convergence could unlock trillion‑dollar markets and redefine longevity, making it a strategic priority for investors and innovators alike.

Key Takeaways

• AI venture capital hit $100B in 2024, up 80%.
• AI now captures ~50% of all VC funding worldwide.
• Agentic AI will become niche platforms, not commodity.
• CRISPR corrected a fatal CPS1 mutation in newborn.
• Merging AI with genomics could extend healthy lifespan to 150.

Summary

The panel highlighted an unprecedented surge in AI financing, with global venture capital pouring over $100 billion into artificial‑intelligence ventures in 2024 – an 80% jump from the previous year and accounting for roughly half of all VC dollars. Speakers warned that while the market feels frothy, the capital influx signals a structural shift toward AI‑driven business models.

Beyond raw funding, the discussion turned to the emerging concept of “agentic AI,” which panelists argue will not become a commoditized utility but will instead fragment into specialized platforms serving distinct verticals, much like today’s social‑media ecosystems. The most compelling growth area, however, is the convergence of AI with biotechnology, where machine‑learning tools can decode genomes as readily as language models parse text.

A vivid illustration came from a recent CRISPR success in Philadelphia: a newborn with a lethal CPS1 liver‑mutation had a single erroneous DNA letter corrected, dramatically improving his prognosis. The speakers likened reading a genome to interpreting code, suggesting that AI‑enhanced gene editing could soon become routine, potentially extending human healthspan to unprecedented lengths.

For investors, the takeaway is clear: capital should flow not only into pure‑play AI startups but also into firms that fuse AI with life‑science platforms. The intersection promises breakthroughs in personalized medicine, longevity, and new revenue streams, reshaping both the biotech and technology landscapes.

Original Description

At our Super Summit investor panel, leading voices break down the explosive growth of AI investment—over $100B globally and rising fast.

From the surge in venture capital flowing into AI (nearly 50%) to the future of agentic AI transforming every industry, this discussion dives deep into where the real opportunities lie.

We also explore one of the most powerful intersections in technology today: AI and biology. Hear the incredible real-world story of a life-saving CRISPR gene edit—and what it means for the future of healthcare, longevity, and human potential.

Key topics:

The AI investment boom and market trends

Why agentic AI won’t be a commodity

Real-world use cases shaping the next decade

AI + biology breakthroughs (CRISPR, genomics)

The future of health, longevity, and innovation